Arginine

Arginine

SCHEMBL23248653

CCC(C)C(N)C(=O)O.N=C(N)NCCCC(N)C(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACES1PR1S1PR4S1PR5

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PRCP P42785 3/20 0.38
NOS2 P35228 3/20 0.34
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
DPP7 Q9UHL4 1/20 0.33
OTC P00480 1/20 0.33
DDAH1 O94760 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPK8 P45983 1/20 0.31
MAPK9 P45984 1/20 0.31
MAPK10 P53779 1/20 0.31
TLR2 O60603 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL11905093 1.00 PRCP (0.38) PRCPNOS2NOS3NOS1DPP7
Arginine SCHEMBL14841994 1.00 PRCP (0.38) PRCPNOS2NOS3NOS1DPP7
Arginine SCHEMBL25168271 0.97 PRCP (0.36) PRCPNOS2NOS3NOS1DPP7
Arginine SCHEMBL11905292 0.97 PRCP (0.35) PRCPNOS2NOS3NOS1DPP7
Arginine SCHEMBL17982370 0.96 PRCP (0.36) PRCPNOS2NOS3NOS1DPP7
Arginine SCHEMBL2501111 0.96 PRCP (0.36) PRCPNOS2NOS3NOS1DPP7
Arginine SCHEMBL1551248 0.95 PRCP (0.35) PRCPNOS2NOS3NOS1DPP7
Arginine SCHEMBL25171512 0.92 PRCP (0.33) PRCP
Arginine SCHEMBL4223569 0.92 PRCP (0.33) PRCPKMT2AMAPK8MAPK9MAPK10
Arginine SCHEMBL28465970 0.91 PRCP (0.33) PRCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113677690-B Peptides for alleviating hair loss and promoting hair growth, cosmetic composition and pharmaceutical composition containing the same 因科斯医药公司 2024-03-12 CN disclosed
EP-4047008-A2 PEPTIDE FOR REDUCING HAIR LOSS AND PROMOTING HAIR GROWTH, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Incospharm Corporation (KR) 2022-08-24 EP disclosed
US-20220160608-A1 PEPTIDE FOR REDUCING HAIR LOSS AND PROMOTING HAIR GROWTH, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME INCOSPHARM CORPORATION (KR) 2022-05-26 US disclosed
CN-113677690-A Peptide for alleviating hair loss and promoting hair growth, cosmetic composition and pharmaceutical composition comprising the same 因科斯医药公司 2021-11-19 CN disclosed
WO-2021075791-A2 PEPTIDE FOR REDUCING HAIR LOSS AND PROMOTING HAIR GROWTH, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 인코스팜 2021-04-22 WO disclosed
WO-2021075792-A1 PEPTIDE COMPOSITION FOR IMPROVING SCALP HEALTH AND ALLEVIATING HAIR LOSS 주식회사 인코스팜 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160608-A1 PEPTIDE FOR REDUCING HAIR LOSS AND PROMOTING HAIR GROWTH, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME MMP7, MMP13, MMP9 PRCP 184/4885NOS2 1333/4885NOS3 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.